References
- BakerMStringerFStephensP2006Pharmacokinetic properties of the anti-TNF agent certolizumab pegol [abstract]Ann Rheum Dis65175
- BrennanEChantryDJacksonA1989Inhibitory effect of TNF antibodies on synovial cell interleukin-1 production in rheumatoid arthritisLancet224472569055
- BuchMHConaghanPGQuinnMA2004True infliximab resistance in rheumatoid arthritis: a role for lymphotoxin alpha?Ann Rheum Dis631344615033655
- ChoyEHHazelmanBSmithM2002Efficacy of a novel PEGylated humanised anti-TNF fragment (CDP870) in patients with rheumatoid arthritis:a Phase II double blinded, randomised, dose-escalating trialRheumatology411133712364632
- ChuCQFieldMFeldmanM1991Localisation of tumour necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritisArthritis Rheum341125321930331
- EmeryPSmolenJChoyE2002CDP870, a novel, humanised tumour necrosis factor alpha inhibitor improves HRQOL. Late breaking abstractEuropean League Against Rheumatism Annual Conference
- FeltsWYelinE1989The economic impact of the rheumatic diseases in the united statesJ Rheumatol16867842527991
- FossatiGNesbittA2006aIn vitro complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity by the anti-TNF agents certolizumab pegol, adalimumab, etanercept and infliximab [abstract]Ann Rheum Dis65455
- FossatiGNesbittA2006bEffect of the anti-TNF agents certolizumab pegol, adalimumab, etanercept and infliximab on levels of apoptosis in activated peripheral blood lymphocytes and monocytes and on necrosis and degranulation of peripheral blood granulocytes [abstract]Ann Rheum Dis65622
- GramlickAFossatiGHenryA2006Assessment of the affinity for soluble TNF and the neutralising potency against soluble and membrane TNF of the anti-TNF agents certolizumab pegol, adalimumab, etanercept and infliximab [abstract]Ann Rheum Dis65456
- HyrichKSymmonsDWatsonK2006Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis:results from the British Society for Rheumatology Biologics RegisterArthritis Rheum5417869416736520
- KaushikVMootsR2005CDP-870 (certolizumab) in rheumatoid arthritisExpert Opin Biol Ther5601615934837
- KefferJProbertLCazlarisH1991Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritisEMBO J104025311721867
- KeystoneEChoyEKaldenJ2001CDP870, a novel, PEGylated humanised TNF-inhibitor is effective in treating the signs and symptoms of rheumatoid arthritis. Late breaking abstract 3American College of Rheumatology Annual Conference
- MehvarR2000Modulation of the pharmacokinetics and pharmacodynamics of proteins by polyethylene glycol conjugationJ Pharm Pharmaceut Sci312536
- MootsRTaggartAWalkerD2003Biologic therapy in clinical practice: enthusiasm must be tempered by cautionRheumatology42614612709535
- MpofuSFatimaFMootsRJ2005Anti-TNF-alpha therapies:they are all the same (aren’t they?)Rheumatology44271315561736
- Pharmacia Corp2001Results presented on Phase II study of investigational drug to test the reduction of signs and symptoms of rheumatoid arthritis [press release]. Accessed 8 November 2006. URL: http://www.pslgroup.com/dg/20D746.htm
- UCB Pharma2004Positive preliminary results from 2nd pivotal CDP870 Phase III trial in rheumatoid arthritis [press release]. Accessed 8 November 2006. URL: http://www.medicalnewstoday.com/medicalnews.php?newsid=13761